LTFS
CLDX icon

Ladenburg Thalmann Financial Services’s Celldex Therapeutics CLDX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2K Sell
1,069
-599
-36% -$1.39K ﹤0.01% 5043
2019
Q3 		$4K Buy
1,668
+1,164
+231% +$2.69K ﹤0.01% 4754
2019
Q2 		$1K Hold
504
– – ﹤0.01% 5081
2019
Q1 		$2K Buy
504
+11
+2% +$58 ﹤0.01% 4912
2018
Q4 		$1K Sell
493
-600
-55% -$2.95K ﹤0.01% 5012
2018
Q3 		$7K Buy
1,093
+1,066
+3,948% +$7.46K ﹤0.01% 4435
2018
Q2 		$1K Hold
27
– – ﹤0.01% 4963
2018
Q1 		$1K Hold
27
– – ﹤0.01% 4963
2017
Q4 		$1K Hold
27
– – ﹤0.01% 4880
2017
Q3 		$1K Hold
27
– – ﹤0.01% 4773
2017
Q2 		$1K Sell
27
-58
-68% -$2.56K ﹤0.01% 4710
2017
Q1 		$5K Buy
85
+40
+89% +$2.08K ﹤0.01% 4290
2016
Q4 		$2K Sell
45
-25
-36% -$1.42K ﹤0.01% 4513
2016
Q3 		$4K Buy
70
+13
+23% +$810 ﹤0.01% 4248
2016
Q2 		$4K Sell
57
-31
-35% -$1.97K ﹤0.01% 4202
2016
Q1 		$5K Sell
88
-16
-15% -$1.8K ﹤0.01% 4055
2015
Q4 		$24K Sell
104
-20
-16% -$4.36K ﹤0.01% 3081
2015
Q3 		$20K Buy
124
+38
+44% +$10.8K ﹤0.01% 3097
2015
Q2 		$33K Buy
86
+27
+46% +$10.7K ﹤0.01% 2871
2015
Q1 		$24K Sell
59
-29
-33% -$10.4K ﹤0.01% 3069
2014
Q4 		$24K Buy
88
+80
+1,000% +$19.9K ﹤0.01% 2861
2014
Q3 		$1K Sell
8
-197
-96% -$42.9K ﹤0.01% 3785
2014
Q2 		$50K Buy
205
+65
+46% +$14.7K ﹤0.01% 2041
2014
Q1 		$37K Buy
140
+13
+10% +$4.98K ﹤0.01% 2158
2013
Q4 		$46K Sell
127
-703
-85% -$271K ﹤0.01% 1967
2013
Q3 		$441K Buy
830
+47
+6% +$16.1K 0.02% 704
2013
Q2 		$183K Buy
+783
New +$154K 0.01% 1011

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CLDX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Celldex Therapeutics (CLDX) stake by 36% in Q4 2019, selling an estimated $1.39K and leaving 1,069 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #5043.

Ladenburg Thalmann Financial Services first reported a position in CLDX in Q2 2013 and has held it in 27 quarters since. The position peaked at $441K in Q3 2013. 48 funds tracked by Wall St. Rank hold CLDX as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 1,069 shares of Celldex Therapeutics worth $2K as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 599 Celldex Therapeutics shares in Q4 2019, an estimated $1.39K.
  • Celldex Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5043 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 27 quarters since.
  • Ladenburg Thalmann Financial Services's Celldex Therapeutics position peaked at $441K in Q3 2013.
  • 48 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.